Veeva Systems (VEEV) Stock
Cloud software platform for life sciences companies. Here's the price, business snapshot, and what's worth knowing about Veeva Systems in June 2026.
Veeva Systems (VEEV) is a cloud‑software company focused on the life sciences industry, providing CRM, clinical, regulatory, quality and data platforms designed for pharmaceutical, biotech and medical‑device firms. It operates a subscription‑based model with high recurring revenue, which has supported steady margins and cash generation as the sector digitises. Key growth drivers include continued R&D outsourcing, regulatory complexity that favours specialised vendors, international expansion and cross‑selling of new modules to existing customers. Investors should note Veeva’s exposure to the healthcare sector and customer concentration in large pharma, which can amplify cyclicality. The shares currently reflect a premium for software‑like margins and growth; valuation and future revenue growth are important to watch. This is general information, not personal financial advice — returns can be volatile and past performance is not a guarantee. Consider whether the company’s sector concentration and valuation fit your risk tolerance and investment horizon.
Why It's Moving
Veeva’s 2026 upside case is being driven by analyst confidence in durable growth and margin expansion.
- Analyst coverage remains broadly constructive, with multiple firms maintaining Buy-leaning views and emphasizing that Veeva’s business model can sustain growth without sacrificing margins.
- Recent research flagged continued momentum in Commercial and newer products, which matters because it suggests the company is broadening its growth base rather than relying on one core segment.
- The bullish setup is also tied to expectations that Veeva can keep converting operating leverage into earnings power, making the stock more sensitive to any upside surprise in future results.
Veeva’s 2026 upside case is being driven by analyst confidence in durable growth and margin expansion.
- Analyst coverage remains broadly constructive, with multiple firms maintaining Buy-leaning views and emphasizing that Veeva’s business model can sustain growth without sacrificing margins.
- Recent research flagged continued momentum in Commercial and newer products, which matters because it suggests the company is broadening its growth base rather than relying on one core segment.
- The bullish setup is also tied to expectations that Veeva can keep converting operating leverage into earnings power, making the stock more sensitive to any upside surprise in future results.
When is the next earnings date for VEEVA SYSTEMS INC (VEEV)?
The next earnings date for Veeva Systems (VEEV) is expected on June 3, 2026, after market close. It should cover the company’s fiscal first quarter of 2027, based on Veeva’s reporting calendar and typical quarterly cadence. This timing is consistent with the company’s historical pattern of early-June reporting following its fiscal year-end in January.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Veeva Systems' stock with a target price of $284.39, indicating strong growth.
Financial Health
Veeva Systems is performing well with strong revenue, profits, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring VEEV
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketHealthcare's Efficiency Imperative
UnitedHealth Group's recent profit miss, driven by high medical costs, has triggered a major cost-cutting initiative across the company. This move signals a broader industry trend, creating an investment opportunity in companies that provide AI and technology solutions to help healthcare organizations improve efficiency and reduce operational expenses.
Published: July 30, 2025
Explore BasketSaaS & Cloud Computing
Invest in the digital revolution that's reshaping how businesses operate worldwide. This collection of carefully selected stocks represents companies at the forefront of software innovation, cloud technology, and digital transformation.
Published: May 23, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue model
Subscription contracts create predictable revenue and strong margins, though future growth depends on new customer wins and cross‑selling to existing clients.
Global pharma footprint
Veeva benefits from long relationships with major pharmaceutical companies and international expansion, but customer concentration can increase sector sensitivity.
Product innovation focus
Ongoing investment in specialised modules and data services supports cross‑sell opportunities, though competition and regulatory changes can affect adoption rates.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
